auristatin e

Auristatin E, a cytotoxic tubulin modifier, disrupts cell division by inhibiting tubulin polymerisation. This compound demonstrates potent and selective antitumor activities, serving as an MMAE analog and cytotoxin in antibody-drug conjugates.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

Aminobenzenesulfonic auristatin E is a potent antitumor agent-linker conjugate for Antibody-Drug Conjugates (ADC). It utilizes Auristatin E (a cytotoxic tubulin modifier) connected through the ADC linker, Aminobenzenesulfonic [1], to exhibit significant antitumor activity.

Aminobenzenesulfonic Auristatin E TFA, an agent-linker conjugate for ADC, exhibits potent antitumor activity. It employs Auristatin E (a cytotoxic tubulin modifier) connected through the ADC linker Aminobenzenesulfonic [1].

AminobenzenesulfonicauristatinE-d8 is a deuterated version of AminobenzenesulfonicauristatinE, which forms part of an antibody-drug conjugate. This compound is synthesized by linking the cytotoxic microtubule modifier Auristatin E with the ADC linker Aminobenzenesulfonic, endowing it with antitumor activity.

(4R,5S)-MonomethylauristatinE intermediate-6 is an intermediate reactant in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity and is widely utilized as the cytotoxic component in antibody-drug conjugates (ADC Cytotoxin).

MonomethylauristatinE intermediate-8 is an intermediate compound in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) acts as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

MonomethylauristatinE intermediate-10 is an intermediate used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs) [ADC Cytotoxin].

MonomethylauristatinE intermediate-17 is an intermediate compound used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) functions as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

Monomethyl auristatin E (MMAE) (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.

D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE.

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.

MMAU (β-D-Glucuronylmonomethylauristatin E) is a payload that is relatively stable in its unbound free state. Lysosomal enzymes convert it to a deglycosylated state, which activates the cytotoxicity of the payload.

m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC) for Trastuzumab, positioned distally from the monomethyl auristatin E (MMAE) payload to produce an ADC with modified hydrophilicity, antigen binding, and in vitro potency[1].

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a potent tubulin inhibitor and toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2, serving as the cytotoxic component in this formulation.

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, is conjugated via a DBCO-(PEG)3-vc-PAB linker.

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the cleavable linker SC-VC-PAB[1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker composed of the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the SuO-Val-Cit-PAB peptide.

Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), incorporating the tubulin inhibitor monomethyl auristatin E (MMAE) and linked via the cleavable Azido-PEG4-Val-Cit-PAB-OH.

Fmoc-MMAE, a protective group-conjugated variant of monomethyl auristatin E (MMAE), serves as a powerful inhibitor of tubulin. It finds application in the synthesis of antibody-drug conjugates (ADC).

Dov-Val-Dil-OH is a useful chemical intermediate for synthesis of auristatin-related compounds, such as Monomethyl auristatin E (MMAE), Auristatins are antimitotic agents which inhibits cell division by blocking the polymerisation of tubulin.

MC-VA-PABC-MMAE is a conjugate composed of the ADC linker peptide MC-VA-PABC and the cytotoxic agent monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization [1] [2]. It functions as an agent-linker module for antibody-drug conjugates (ADCs).